151 related articles for article (PubMed ID: 10691826)
21. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
22. Prostate cancer in Western Australia: trends in incidence and mortality from 1985 to 1996.
Threlfall TJ; English DR; Rouse IL
Med J Aust; 1998 Jul; 169(1):21-4. PubMed ID: 9695697
[TBL] [Abstract][Full Text] [Related]
23. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden.
Jonsson H; Holmström B; Duffy SW; Stattin P
Int J Cancer; 2011 Oct; 129(8):1881-8. PubMed ID: 21154740
[TBL] [Abstract][Full Text] [Related]
24. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons.
Quinn M; Babb P
BJU Int; 2002 Jul; 90(2):162-73. PubMed ID: 12081758
[TBL] [Abstract][Full Text] [Related]
25. Incidence and factors predicting the detection of prostate cancer after transurethral resection of the prostate for clinically benign disease.
Bright EA; Manuel C; Goddard JC; Khan MA
Urol Int; 2009; 83(2):171-4. PubMed ID: 19752612
[TBL] [Abstract][Full Text] [Related]
26. Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia.
Luo Q; Yu XQ; Kahn C; Egger S; Patel MI; Grogan PB; Caruana M; Canfell K; Smith DP; O'Connell DL
Cancer Epidemiol; 2022 Jun; 78():102159. PubMed ID: 35447540
[TBL] [Abstract][Full Text] [Related]
27. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer screening in Tyrol, Austria: experience and results.
Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
[TBL] [Abstract][Full Text] [Related]
29. Mass screening of prostate cancer in Changchun City of China.
Li X; Tsuji I; Kuwahara M; Zhang H; Wang H; Zhang L; Ji G; Zhao X
Int Urol Nephrol; 2004; 36(4):541-8. PubMed ID: 15787333
[TBL] [Abstract][Full Text] [Related]
30. Comparison of prostate cancer survival in Germany and the USA: can differences be attributed to differences in stage distributions?
Winter A; Sirri E; Jansen L; Wawroschek F; Kieschke J; Castro FA; Krilaviciute A; Holleczek B; Emrich K; Waldmann A; Brenner H;
BJU Int; 2017 Apr; 119(4):550-559. PubMed ID: 27208546
[TBL] [Abstract][Full Text] [Related]
31. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.
Jacobsen SJ; Katusic SK; Bergstralh EJ; Oesterling JE; Ohrt D; Klee GG; Chute CG; Lieber MM
JAMA; 1995 Nov; 274(18):1445-9. PubMed ID: 7474190
[TBL] [Abstract][Full Text] [Related]
32. PSA measurement and prostate cancer--overdiagnosis and overtreatment?
Breidablik HJ; Meland E; Aakre KM; Førde OH
Tidsskr Nor Laegeforen; 2013 Sep; 133(16):1711-6. PubMed ID: 24005707
[TBL] [Abstract][Full Text] [Related]
33. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
34. Unravelling the prostate-specific antigen controversy: a West of Scotland perspective.
Zafar N; Miller S; Leburn V; Qureshi KN; Rajan P
Scott Med J; 2014 May; 59(2):126-9. PubMed ID: 24682103
[TBL] [Abstract][Full Text] [Related]
35. The diminishing role of transurethral resection of the prostate.
Merrill RM; Hunter BD
Ann Surg Oncol; 2010 May; 17(5):1422-8. PubMed ID: 20091426
[TBL] [Abstract][Full Text] [Related]
36. Kinetics of serum total and free prostate-specific antigen (PSA) after extended multisite prostate biopsy: Comparison among biopsy, transurethral resection of the prostate (TURP), and biopsy plus TURP.
Hara N; Koike H; Nobushita T; Miyajima N; Kawaguchi M; Nishiyama T; Takahashi K; Hohenfellner R
Urol Oncol; 2010; 28(4):355-9. PubMed ID: 19110451
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer diagnosed after prostate-specific antigen testing of men without clinical signs of the disease: a population-based study from the National Prostate Cancer Register of Sweden.
Bratt O; Berglund A; Adolfsson J; Johansson JE; Törnblom M; Stattin P;
Scand J Urol Nephrol; 2010 Dec; 44(6):384-90. PubMed ID: 20624113
[TBL] [Abstract][Full Text] [Related]
38. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
39. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.
Etzioni R; Penson DF; Legler JM; di Tommaso D; Boer R; Gann PH; Feuer EJ
J Natl Cancer Inst; 2002 Jul; 94(13):981-90. PubMed ID: 12096083
[TBL] [Abstract][Full Text] [Related]
40. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
